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Abstract
Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to
the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted
expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this
study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical
prostatectomy (RP).
Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue
samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up
(range, 1 to 14 years).
Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was
significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly
correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA
levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28,
95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with
the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy
Gleason score.
Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients
with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and
treatment.
Background
Prostate cancer (PCa) is the most common malignancy
and the second leading cause of male cancer-related
death in the U.S. [1]. The introduction of serum pros-
tate-specific antigen (PSA) has dramatically altered and
benefited the initial diagnosis of men with PCa. How-
ever, the widespread use of PSA testing has resulted in
over-detection and over-treatment of potentially indo-
lent disease [2]. Therefore, there is a dire need for better
tools to differentiate men that will benefit from
definitive therapy from those in whom an active surveil-
lance program may be appropriate. Therefore, in addi-
tion to the currently utilized clinical information, we
also need better markers that are able to identify men
that need definitive or adjuvant therapy after radical
prostatectomy (RP).
The Cancer/Testis Antigens (CTAs) are a group of
proteins that in the normal adult are typically restricted
to the testis but are aberrantly expressed in several types
of cancers [3]. Although CTAs are generally highly
expressed in testis, these genes exhibit heterogeneous
expression profiles, and can be classified into testis-
restricted, testis/brain-restricted, and testis-selective
groups of genes that show additional expression in
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broadly divided into two groups based on their chromo-
somal location: the CT-X antigens located on the ×
chromosome and non-X CT antigens located on various
autosomes. In the normal testis, the CT-X genes are
generally expressed in the spermatogonia, the proliferat-
ing germ cells [5]. On the other hand, expression of
non-X CT genes appears more dominant in the later
stages of germ-cell differentiation, such as in spermato-
cytes [5]. In several types of cancers, individual CTAs
are often associated with advanced disease with poorer
outcomes in addition to their specific expression pat-
terns [6-11]. Additionally, we recently demonstrated that
there is a remarkable stage-specific expression of the
CTAs in PCa [12]. These observations raised the possi-
bility that the CTAs might serve as unique biomarkers
that could potentially be used to distinguish men with
aggressive disease who need treatment from men with
indolent disease not requiring immediate intervention in
PCa.
In this study, by mining publicly available microarray
data in conjunction with data on CTA expression that
we obtained using a custom CT microarray [12], we
explored CTAs that were associated with disease recur-
rence following RP.
Methods
Clinical samples
Prostate tissue specimens from 72 clinically localized
PCa cases with follow-up data (29 without recurrence
and 43 with recurrence) and 17 clinically localized PCa
without follow-up data were collected and frozen at the
time of radical prostatectomy (RP), from 1993 to 2007,
at the Johns Hopkins Hospital. Twenty histologically
normal samples of prostate tissues were collected from
cancer-free regions of surgical specimens obtained at
the time of RP. The tissue specimens were processed as
described previously before RNA extraction [13]. OCT-
embedded frozen tissue blocks were manually trimmed
to enrich the content of target tissue lesions (e.g., nor-
mal or cancer) prior to sectioning and RNA extraction.
For tumor samples, tumor cells made up more than
70% of the tissue content (calculated by averaging the %
tumor content in the first and last sections) in all cases
[14]. Metastatic PCa tissues (n = 21) were collected
from soft tissue metastasis of patients who died from
PCa, as part of the Johns Hopkins Autopsy Study of
lethal PCa [15]. Autopsy RNA specimens had high qual-
ity as assessed by RNA index number (RIN), and were
prepared and processed as previously described [16,17].
Twenty normal prostate tissues, 17 localized PCa with-
out follow-up data and 21 metastatic PCa samples were
used to validate the microarray data obtained from data-
base (Additional file 1). Seventy two localized PCa
samples were used to investigate whether selected CTAs
were associated with disease recurrence following RP.
The use of surgical and autopsy specimens for molecu-
lar analysis was approved by the Johns Hopkins Medi-
cine Institutional Review Boards. Biochemical
recurrence was defined as a postoperative elevation of
serum PSA (0.2 ng/ml or greater) after RP [18,19]. The
endpoint of the follow-up in this study was the time to
biochemical recurrence.
Quantitative singleplex and multiplex real-time PCR
First strand cDNA was made from 0.5 μgR N Au s i n g
iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.,
Hercules, CA) following the manufacturer’sp r o t o c o li n
a total volume of 20 μl. All primers and probes (Addi-
tional file 2) were obtained from Integrated DNA Tech-
nologies (Coralville, IA). Quantitative singleplex and
multiplex real-time PCR were carried out with the
CFX96 Real-Time PCR Detection System (Bio-Rad
Laboratories, Inc.). The singleplex PCR reactions were
performed with 0.2 μl of cDNA template in 25 μlo f
reaction mixture containing 12.5 μlo fi QS Y B RG r e e n
Supermix (Bio-Rad Laboratories, Inc.) and 0.25 μmol/L
each primer. PCR reaction was subjected to hot start at
95°C for 3 minutes followed by 45 cycles of denatura-
tion at 95°C for 10 seconds, annealing at 60°C for 30
seconds, and extension at 72°C for 1 minute. Quantita-
tive multiplex real-time PCR reaction was carried out
with 0.2 μl of cDNA template in 25 μl of reaction mix-
ture containing 12.5 μl of iQ Multiplex Powermix (Bio-
Rad Laboratories, Inc.), 0.3 μmol/L each primer and 0.2
μmol/L probe. The reaction was subjected to hot start
at 95°C for 3 minutes followed by 45 cycles of denatura-
tion at 95°C for 10 seconds, and annealing and exten-
sion at 60°C for 60 seconds. Amplification of b-actin
was used as a control for RNA integrity for all samples.
We confirmed that almost identical results were
obtained when using TATA binding protein as a refer-
ence gene instead of b-actin (data not shown). A refer-
ence RNA from pooled cells and prostate tissue were
included on each plate to provide standardization across
PCR plates. Analysis and fold-change differences were
determined using the comparative CT method. Fold
change was calculated from the ΔΔCT values with the
formula 2
-ΔΔCT.
Statistical analysis
CTA expression was normalized by dividing each indivi-
d u a lv a l u eb yt h e i rr e s p e c t i v eb-actin value. Distribu-
tions of normalized CTAs were compared among
categories of prognostic factors using the Wilcoxon test
(for binary factors) or Kruskal-Wallis test (for factors
with more than 2 categories). Correlations between the
normalized CTAs and other continuous variables were
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tion coefficient. Normalized CTAs were dichotomized at
the median of the distribution among prostate cancer
patients who did not have a recurrence. Risk of recur-
rence associated with CTAs was evaluated in univariate
and multivariable proportional hazards models. All sta-
tistical analyses were performed with SAS v9.2 (SAS
Institute, Cary, NC).
Results
Selection of candidate CTAs
By mining publicly available microarray data from the
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo in conjunction with our own data [12], we first
selected candidate CT-X and non-X CTAs for
investigation. As described in Additional file 1, the CT-
X antigens (SSX2, CSAG2, MAGEA2, and MAGEA12)
were highly up-regulated only in metastatic PCa but
were not expressed in benign and primary PCa. The
highest expression of non-X CT antigens (CEP55,
NUF2, PBK and TKK) was seen in metastatic PCa simi-
lar to the CT-X antigens; however the non-X CT anti-
gens were also up-regulated in primary PCa compared
to benign prostate disease. Interestingly, a member of
the CT-X antigen family, PAGE4, was highly expressed
in benign and primary PCa but not in metastatic PCa.
To validate the microarray data, we performed quantita-
tive real-time PCR using samples from normal prostate (n
= 20), clinically localized PCa (n = 17) and metastatic PCa
(n = 21) (Figure 1). Consistent with the microarray data,
Figure 1 Cancer/Testis Antigen (CTA) expression in prostate tissues. CTA expression in normal prostate tissue (NP) (n = 20), clinically
localized prostate cancer (L-PCa) (n = 17) and metastatic prostate cancer (M-PCa) (n = 21). (A) CEP55, (B) NUF2, (C) PBK, (D) TTK, (E) PAGE4, (F)
SSX2/3, (G) CSAG2, (H) MAGEA2, (I) MAGEA12. * p < 0.05, **p < 0.01.
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expressed in metastatic disease. Furthermore, the expres-
sion of four non-X CT antigens (CEP55, NUF2, PBK and
TKK) was significantly different between normal prostate
and clinically localized PCa. In contrast, there were no sig-
nificant differences between normal prostate and clinically
localized PCa for the four CT-X antigens namely, SSX2,
CSAG2, MAGEA2, and MAGEA12. However, PAGE4
showed the highest expression in normal prostate but was
significantly down-regulated in metastatic samples.
The aim of this study was to determine if CTAs are
associated with disease recurrence after radical prosta-
tectomy (RP). Since the following five CTAs, CEP55,
NUF2, PBK, TKK and PAGE4 showed differential
expression in both clinically localized PCa and meta-
static PCa compared to normal prostate, we selected
these five CTAs for developing a multiplex PCR assay
that has the potential to stratify patients with and with-
out PCa recurrence after RP.
Association of CTA expression with recurrence in radical
prostatectomy patients
In order to characterize the selected CTAs, we analyzed 72
samples from PCa patients who underwent radical prosta-
tectomies for their disease (29 patients without recurrence
and 43 patients with recurrence). Characteristics of the
prostatectomy patients are described in Table 1. In this
cohort, 36% of the patients had Gleason 8-10 and a fairly
large fraction (60%) experienced biochemical recurrence
within a median of 1 year follow-up (range, 1 to 8 years),
indicating that this cohort was a very high risk cohort. As
shown in Figure 2A-D, CEP55 (p < 0.0001), NUF2 (p <
0.0001), PBK (p = 0.0045) and TTK (p = 0.0386) were sig-
nificantly higher in prostate samples from patients with
recurrent disease. In contrast, PAGE4 (p = 0.0019) was
significantly lower in the same patients (Figure 2E). How-
ever, there was no significant difference in the CT-X anti-
gens (SSX2, CSAG2, MAGEA2, and MAGEA12) between
patients with or without recurrence (data not shown).
Association of CTA expression with clinicopathological
parameters
We next compared CTA expression patterns with prog-
nostic variables such as the age of patients, preoperative
PSA, Gleason grade, and tumor stage. All of the CTAs
with the exception of TTK, were significantly correlated
with the prostatectomy Gleason score (CEP55; p =
0.0057, NUF2; p = 0.0051, PBK; p = 0.0295, PAGE4; p =
0.0236); however none were correlated with age, preo-
perative PSA and tumor stage.
Association of CTA expression with biochemical-free survival
Kaplan-Meier analyses were performed with dichoto-
mized CTA expression (according to the median) and
the time parameter of biochemical-free survival. Higher
expression of CEP55 and NUF2 was significantly corre-
lated with shorter biochemical recurrence-free time
(Figure 3A, B). In contrast, higher expression of
PAGE4 was significantly correlated with longer bio-
chemical recurrence-free time (Figure 3C). In univari-
ate proportional hazards models, CEP55 (HR = 3.59,
95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95%
CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95%
CI: 0.21-0.93), p = 0.031 were significantly associated
w i t ht h er i s ko fP C ar e c u r r e n c e( T a b l e2 ) .M u l t i v a r i -
able proportional hazards models evaluated the effect
of established prognostic factors including age, PSA,
pathologic stage, and prostatectomy Gleason score;
only the latter was statistically significant in the multi-
variable model. Each CTA was tested individually in a
multivariable model that also adjusted for prostatect-
omy Gleason score (Table 3). None of the CTAs
retained statistical significance after adjustment for
Table 1 Characteristics of the prostatectomy patients
evaluated (1993-2007)
Men without
Recurrence
(n = 29)
Men with
Recurrence
(n = 43)
P
Value
Follow-up period
(years)
Mean ± SD 5.3 ± 3.1 1.7 ± 1.4
Median 5 1
Interquartile range 4 1
Range 1-14 1-8
Age at surgery (years)
Mean ± SD 54.8 ± 6.7 59.4 ± 6.9 < 0.01
Median 54 61
Range 43-68 41-71
Preoperative PSA
(ng/ml)
Mean ± SD 7.9 ± 6.7 12.9 ± 8.8 < 0.01
Median 6.1 10.7
Range 1.7-31.6 3.7-37.4
Pathological Gleason
sum, n (%)
≤ 6 20 (70.0) 1 (2.3) < 0.001
7 (3 + 4) 3 (10.3) 13 (30.2)
7 (4 + 3) 2 (6.9) 7 (16.3)
8-10 4 (13.8) 22 (51.2)
Pathological stage,
n (%)
OC (EPE-, SV-, LN-) 10 (34.5) 2 (4.7) < 0.001
EPE+ (SV-, LN-) 16 (55.2) 20 (46.5)
SV+ (EPE+/-, LN-) 3 (10.3) 9 (20.9)
LN+ (EPE+/-, SV
+/-)
0 12 (27.9)
PSA, prostatic-specific antigen; OC, organ-confined; EPE, extra-prostatic
extension; SV, seminal vesicle; LN, lymph node; CTAs, Cancer/Testis Antigens
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this cohort the CTAs are not independent predictors
of biochemical recurrence.
Discussion
If we acknowledge that we are currently ‘over-detecting’
PCa as a result of PSA-based screening, then there is a dire
need to develop new biomarkers to improve the over-
detection (and consequently, over-treatment) of potentially
indolent disease. Unfortunately, currently available biomar-
kers are unable to discern indolent from aggressive disease.
Recently, we demonstrated the potential of the CTAs
to serve as novel biomarkers for differentiating organ-
confined PCa and metastatic PCa [12]. In this study, we
identified several CTAs that are differentially expressed
in normal prostate, localized PCa, and metastatic PCa
tissues. From this initial set, we identified five CTAs
that are differentially expressed between patients with
and without disease recurrence after RP. Furthermore,
we demonstrated that 3 of these CTAs (CEP55, NUF2
and PAGE4) were significantly associated with the risk
of PCa recurrence. Therefore, these CTAs may repre-
sent good biomarker candidates to predict disease recur-
rence following RP. To our knowledge, this is the first
study analyzing the value of expression levels of CEP55,
NUF2 and PAGE4 in localized PCa treated by RP.
According to the classification of CTAs defined by
Hoffman et al. [4], CEP55 and NUF2 are considered to
be classified as a testis-selective group of genes that
show additional expression in somatic tissues in addi-
tion to the testis (Additional file 3). CEP55 is a centro-
somal protein that plays an essential role in G2/M cell
cycle [20,21] while human NUF2 encodes a protein
that is highly similar to yeast Nuf2. Yeast Nuf2 is a
Figure 2 Cancer/Testis Antigen (CTA) expression in recurrent and non-recurrent prostate cancer. CTA expression in clinically localized
prostate cancer with recurrence (Rec (+)) (n = 43) and without recurrence (Rec (-)) (n = 29). (A) CEP55, (B) NUF2, (C) PAGE4, (D) PBK, (E) TTK.
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with the centromere and plays a regulatory role in
chromosome segregation [22]. Human NUF2 is also
found to be associated with centromeres of mitotic
HeLa cells, which suggests that this protein is a
functional homolog of yeast Nuf2 [23]. Thus, higher
expression of CEP55 and NUF2 in prostate samples
from patients with recurrent disease after RP might be
associated with an inappropriate regulation of G2/M
transition of cell cycle.
Figure 3 Kaplan-Meier analyses. Kaplan-Meier curves showing biochemical recurrence-free survival against time after radical prostatectomy
stratified by the mRNA expression of (A) CEP55, (B) NUF2, (C) PAGE4, (D) PBK, and (E) TTK (high versus low groups dichotomized by median
value).
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expressed in the testis, PAGE4 exhibits a unique expres-
sion pattern (Additional file 3). It is reported that
PAGE4 is expressed both in normal prostate and pros-
tate cancer, but is also expressed in other male and
female reproductive tissues including testis, fallopian
tube, placenta, uterus, and uterine cancer [24]. Further-
more, PAGE4 is known to be up-regulated in sympto-
matic benign prostatic hyperplasia (BPH) [25] and in
PCa [26]. Inconsistent with the previous data, we
demonstrated that PAGE4 showed higher expression in
normal prostate compared to localized PCa. We also
showed that PAGE4 was significantly down-regulated in
metastatic PCa compared to localized PCa. Considering
t h e s er e s u l t s ,w eh y p o t h e s i z e dt h a tP A G E 4m i g h tp l a y
an important role especially in the early stage of PCa
and not be required for disease progression. Because
this patient cohort was very high risk, there is a possibi-
lity that samples of localized PCa used in this study
might have more aggressive phenotype (high metastatic
potential) than those used in other studies. Furthermore,
the normal prostate tissues used in this study were his-
tologically normal prostate samples from surgical speci-
mens with prostate cancer. Normal prostate tissues
obtained from PCa patients might have higher expres-
sion of PAGE4 compared to normal prostate tissues
from healthy donor. However, further examination is
required to validate the down-regulation of PAGE4 with
disease progression of PCa.
It is reported that PCa exhibits moderate expression
levels of CTAs with 30% of the CTAs transcripts hav-
ing an expression frequency of greater than 20% [3]. In
this study, we analyzed the expression levels of CTAs
using quantitative real-time PCR, as opposed to the
end-point RT-PCR commonly used in the previous
studies. We observed that the CTAs were expressed in
Table 2 Univariate proportional hazards models of risk of
biochemical recurrence after prostatectomy associated
with established prognostic factors and individual CTAs*
Variable HR (95% CI) P Value
Age (years) 1.04 (0.999, 1.09) 0.054
PSA (ng/ml) 1.04 (1.004, 1.07) 0.028
Prostatectomy stage
Organ confined 1.0 ref
Extraprostatic extension 4.53 (1.05, 19.47) 0.042
Seminal vesicle involvement 7.49 (1.60, 35.10) 0.011
Lymph node metastases 10.81 (2.37, 49.23) 0.002
Prostatectomy Gleason score
≤ 6 1.0 ref
7 (3 + 4) 26.83 (3.48, 206.73) 0.002
7 (4 + 3) 39.01 (4.65, 327.17) 0.0007
8 to 10 35.01 (4.64, 264.19) 0.0006
CTAs
CEP55 3.59 (1.50-8.60) 0.004
NUF2 2.28 (1.11-4.67) 0.024
PAGE4 0.44 (0.21-0.93) 0.031
PBK 1.78 (0.92-3.43) 0.085
TTK 1.55 (0.82-2.94) 0.179
CTAs, Cancer/Testis Antigens; HR, hazard ratio; CI, confidence interval
* CTAs were dichotomized at the median of the value normalized to actin in
the non-recurrent group. Hazard ratios represent comparison of values greater
than or equal to the median vs. values less than the median.
Table 3 Multivariable proportional hazards models of
risk of biochemical recurrence after prostatectomy
associated with prostatectomy Gleason score and
individual CTAs*
Variable HR (95% CI) P Value
CEP55
CEP55 1.85 (0.76, 4.53) 0.177
Prostatectomy Gleason score
≤ 6 1.0 ref
7 (3 + 4) 22.07 (2.82, 172.74) 0.003
7 (4 + 3) 28.90 (3.34, 250.28) 0.002
8 to 10 29.25 (3.82, 224.08) 0.001
NUF2
NUF2 1.73 (0.83, 3.63) 0.145
Prostatectomy Gleason score
≤ 6 1.0 ref
7 (3 + 4) 25.04 (3.24, 193.72) 0.002
7 (4 + 3) 31.21 (3.66, 266.07) 0.002
8 to 10 33.31 (4.40, 251.92) 0.0007
PAGE4
PAGE4 0.70 (0.33, 1.49) 0.351
Prostatectomy Gleason score
≤ 6 1.0 ref
7 (3 + 4) 24.53 (3.16, 190.61) 0.002
7 (4 + 3) 32.90 (3.83, 282.99) 0.002
8 to 10 32.73 (4.32, 248.21) 0.0007
PBK
PBK 1.40 (0.72, 2.73) 0.321
Prostatectomy Gleason score
≤ 6 1.0 ref
7 (3 + 4) 26.41 (3.42, 203.76) 0.002
7 (4 + 3) 36.04 (4.27, 304.10) 0.001
8 to 10 33.30 (4.40, 252.02) 0.0007
TTK
TTK 1.27 (0.67, 2.42) 0.470
Prostatectomy Gleason score
≤ 6 1.0 ref
7 (3 + 4) 25.56 (3.31, 197.50) 0.002
7 (4 + 3) 38.46 (4.59, 322.31) 0.0008
8 to 10 33.55 (4.44, 253.06) 0.0007
CTAs, Cancer/Testis Antigens; HR, hazard ratio; CI, confidence interval
* CTAs were dichotomized at the median of the value normalized to actin in
the non-recurrent group. Hazard ratios represent comparison of values greater
than or equal to the median vs. values less than the median.
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levels varied significantly. Further study is required to
investigate the frequency of these CTAs in PCa using
immunohistochemical analysis, especially in order to
examine the potential of these CTAs as immunothera-
peutic targets for PCa.
Several points in this report warrant emphasis. First,
in this study, we show that all CTAs with the excep-
tion of TTK were significantly correlated with prosta-
tectomy Gleason score, but none were correlated with
age, preoperative PSA and tumor stage. Although
G l e a s o ns c o r ei sb e l i e v e dt ob eo n eo ft h es t r o n g e s t
predictors of recurrence, it tends to be subjective. As
described, we developed quantitative multiplex real-
time PCR assays to determine CTA expression that in
future should provide consistent and quantitative data
across institutions. Therefore, these have the potential
to be a ‘molecular’ Gleason’s score. Second, cancer
immunotherapy is emerging as a promising modality
for castration- and chemotherapy-resistant PCa [27].
Indeed, many CTAs are immunogenic and their use as
therapeutic cancer vaccines is being evaluated. In fact,
CEP55 and NUF2 have already been shown to be use-
ful targets for immunotherapy [28-30]. Thus, a CTA-
based biomarker can provide information not only for
predicting disease recurrence, but also suggesting treat-
ment options, that can be personalized to the patient.
Third, one of the problems in developing reliable bio-
markers for PCa is heterogeneity. Therefore, a combi-
nation of markers is more likely to provide better
predictive value rather than a single marker. With the
use of a multiplex qPCR assay as the detection plat-
form, there is the potential to expand the test to
include additional transcripts which can enhance assay
performance.
On the other hand, there are several limitations to
t h ep r e s e n ts t u d ya sw e l l .T h ep a t i e n tn u m b e rw a sl i m -
ited and these patients were not consecutively and pro-
spectively collected for this study. Furthermore, we
used a frozen tissue cohort in which selection bias
existed as a result of selection of specimens with large
volume tumors appropriate for frozen tissue collection.
In fact, the patients in this cohort had high Gleason
grade (> 8) (36%), extra-prostatic extension (50%),
seminal vesicle involvement (17%), and lymph node
metastasis (17%), resulting in a high biochemical recur-
rence rate (60%), not reflecting contemporary newly
screened RP population [18,31,32]. Thus, we evaluated
a set of CTAs in such a high risk cohort due to the
selection bias. Therefore, larger and contemporary
cohorts presenting newly diagnosed RP population
across multiple institutions are required for further
validation of these results.
Conclusion
The present study has demonstrated the potential of the
CTAs as a prognostic marker for patients after RP. Tak-
ing it into consideration that currently there is no bio-
marker available to discern indolent from aggressive
disease, these results appear promising although, addi-
tional studies will be required to validate the results in a
larger setting.
Additional material
Additional file 1: Supplemental Table 1. Differential expression of the
Cancer/Testis Antigens in benign prostate, primary prostate cancer, and
metastatic prostate cancer. This file contains the expression data of the
Cancer/Testis Antigens in benign prostate, primary prostate cancer, and
metastatic prostate cancer from the Gene Expression Omnibus http://
www.ncbi.nlm.nih.gov/geo.
Additional file 2: Supplemental Table 2. PCR primer and probe
sequences for quantitative singleplex and multiplex real-time PCR. This
file contains PCR primer and probe sequences used in this study.
Additional file 3: Supplemental Figure 1. Gene expression microarray
data of NUF2, CEP55, PBK, TTK and PAGE4 in various normal tissues.
Gene expression data from various normal tissues for (A) NUF2, (B)
CEP55, (C) PBK, (D) TTK and (E) PAGE4 were extracted from microarray
study [33] annotated in the Oncomine database [34].
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